Français

Central Canada includes Manitoba, Nunavut and Saskatchewan!

Here in the Central Region for Crohn's and Colitis Canada, we have a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and health professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved. Every community, large or small, has the potential to help us improve the lives of those affected by Crohn’s disease and ulcerative colitis, and bring us closer to finding cures.

Coordinator, Development and Community Engagement, Manitoba
Ashley Clarke
aclarke...crohnsandcolitis...ca
403-700-1729

Crohn's and Colitis Canada Office:
416-920-5035 ext. 340 | 1-800-387-1479
 

Events

People walking at a Gutsy Walk park

Gutsy Walk 2026: 30 years walking to stop Crohn’s and colitis

Gutsy Walkers—get ready for 2026! Crohn’s and Colitis Canada’s annual fundraiser is set for Sunday, May 31, in Toronto, and Sunday, June 7, 2026, across Canada. Gutsy Walk is now ...

 • 
Check the Gutsy Walk website for a walk location near you
 • 
2026 Gutsy and Glamorous Gala text on an image of fall leaves in oranges and browns.

2026 Gutsy and Glamourous Gala

This fall, Winnipeg will come together for a night of courage, glamour, and purpose!Join us at the 17th annual Gutsy & Glamorous Gala to help raise vital funds for groundbreaking inflammatory ...

 • 
The Delta | 350 St. Mary Ave.
Winnipeg
 • 
Remember to bookmark this page.

Winnipeg Office

2110-439 University Avenue
Toronto, ON M5G 1Y8

manitoba@crohnsandcolitis.ca 416-920-5035 or 1-800-387-1479

Search by Postal Code

News

“You don’t need to be superhuman”: How a small-town hockey player made it to the NCAA in the face of Crohn’s disease

“You don’t need to be superhuman”: How a small-town hockey player made it to the NCAA in the face of Crohn’s disease

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

 47 48 49 50 51 52 53 54 55 56